LGND Ligand Pharmaceuticals Incorporated

Rice Hall James & Associates LLC reduced its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 12.7% in Q3, now owning 294,490 shares valued at $52.17 million. Despite this trim, LGND remains its third-largest position, representing 2.8% of its investment portfolio. Ligand Pharmaceuticals reported strong earnings with an EPS of $3.09 and revenue of $86.89 million for the quarter, exceeding analyst expectations.

Ligand Pharmaceuticals (LGND) held its 2025 Investor Day, sparking discussions on X about its updated 2026 revenue guidance of $245 million to $285 million and focus on royalty portfolio growth. The stock saw a slight uptick to $195.56, reflecting mixed investor sentiment. Insider trading activity shows 29 sales and no purchases in the last six months, while institutional investors have largely increased their positions.

Legal & General Group Plc increased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 15.8% in Q2, acquiring 16,171 additional shares. This brings their total holding to 118,333 shares, valued at approximately $13.45 million. The biotechnology company reported strong quarterly earnings, beating analyst expectations, and has received multiple price target increases from brokerage firms.

Ligand Pharmaceuticals Inc. (LGND) has seen a 7.23% decrease in its short interest, with 1.11 million shares now sold short, representing 6.8% of available shares. This decline in short interest suggests a potentially more bullish sentiment among investors for the company. Compared to its peers, Ligand Pharmaceuticals Inc. has less short interest on average.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that CEO Todd Davis and CFO Tavo Espinoza will participate in three investor conferences in November 2025. These include one-on-one meetings at the UBS Global Healthcare Conference on November 10, a fireside chat at the Stifel 2025 Healthcare Conference on November 12, and a presentation at the Southwest IDEAS 2025 Investor Conference on November 20. Investors interested in scheduling one-on-one meetings should contact their UBS or Stifel representatives.

Ligand Pharmaceuticals stock reached a new 52-week high, trading at 186.46 USD. This achievement reflects a significant milestone for the company's market performance.